|
|
|
|
|
|
|
|
Full text
Background
Platinum-based combination therapy is the standard first-line treatment for women
with advanced serous epithelial ovarian carcinoma (EOC). However, about 20 % will
not respond and are considered clinically resistant. The availability of biomarkers
to predict responses to the initial therapy would provide a practical approach to
identify women who would benefit from a more appropriate first-line treatment. Ascites
is an attractive inflammatory fluid for biomarker discovery as it is easy and minimally
invasive to obtain. The aim of this study was to evaluate whether six selected inflammation-regulating
factors in ascites could serve as diagnostic or drug resistance biomarkers in patients
with advanced serous EOC.
Methods
A total of 53 women with stage III/IV serous EOC and 10 women with benign conditions
were enrolled in this study. Eleven of the 53 women with serous EOC were considered
clinically resistant to treatment with progression-free survival < 6 months. Ascites
were collected at the time of the debulking surgery and the levels of cytokines were
measured by ELISA. The six selected cytokines were evaluated for their ability to
discriminate serous EOC from benign controls, and to discriminate platinum resistant
from platinum sensitive patients........
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.